CN116249558A - 用于将药物递送至受伤肾脏的树枝状大分子组合物和方法 - Google Patents

用于将药物递送至受伤肾脏的树枝状大分子组合物和方法 Download PDF

Info

Publication number
CN116249558A
CN116249558A CN202180062066.1A CN202180062066A CN116249558A CN 116249558 A CN116249558 A CN 116249558A CN 202180062066 A CN202180062066 A CN 202180062066A CN 116249558 A CN116249558 A CN 116249558A
Authority
CN
China
Prior art keywords
dendrimer
composition
agent
ppar
kidney
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180062066.1A
Other languages
English (en)
Chinese (zh)
Inventor
J·L·克利兰德
K·兰加拉曼努贾姆
S·坎南
R·夏尔马
S·阿皮亚尼拉罗萨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ashwata Therapeutics Co ltd
Original Assignee
Ashwata Therapeutics Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ashwata Therapeutics Co ltd filed Critical Ashwata Therapeutics Co ltd
Publication of CN116249558A publication Critical patent/CN116249558A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180062066.1A 2020-07-17 2021-07-16 用于将药物递送至受伤肾脏的树枝状大分子组合物和方法 Pending CN116249558A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063053228P 2020-07-17 2020-07-17
US63/053,228 2020-07-17
PCT/US2021/042097 WO2022016120A1 (en) 2020-07-17 2021-07-16 Dendrimer compositions and methods for drug delivery to injured kidney

Publications (1)

Publication Number Publication Date
CN116249558A true CN116249558A (zh) 2023-06-09

Family

ID=79555049

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180062066.1A Pending CN116249558A (zh) 2020-07-17 2021-07-16 用于将药物递送至受伤肾脏的树枝状大分子组合物和方法

Country Status (9)

Country Link
US (1) US20230364244A1 (enExample)
EP (1) EP4181913A4 (enExample)
JP (1) JP2023534812A (enExample)
CN (1) CN116249558A (enExample)
AU (1) AU2021310470A1 (enExample)
CA (1) CA3189682A1 (enExample)
IL (1) IL299891A (enExample)
PH (1) PH12023550133A1 (enExample)
WO (1) WO2022016120A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022552818A1 (en) 2020-04-24 2024-03-25 Ashvattha Therapeutics Inc Dendrimer compositions and methods for treatment of severe acute respiratory distress syndrome
EP4237009A4 (en) * 2020-10-30 2025-09-24 Ashvattha Therapeutics Inc Radiolabeled ether dendrimer conjugates for PET imaging and radiotherapy
US20250333732A1 (en) * 2022-05-23 2025-10-30 Empirico Inc. Treatment of sos2 related diseases and disorders
WO2025137151A2 (en) * 2023-12-18 2025-06-26 The Johns Hopkins University Dendrimer compositions for the treatment of atherosclerosis, obesity, and metabolic syndromes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011053618A2 (en) * 2009-10-30 2011-05-05 The Regents Of The University Of Michigan Hydroxyl-terminated dendrimers
CN106573070A (zh) * 2014-08-13 2017-04-19 约翰霍普金斯大学 树枝状聚合物到脑肿瘤的选择性传递
CN108289872A (zh) * 2015-10-29 2018-07-17 约翰霍普金斯大学 树枝状聚合物组合物和其在坏死性小肠结肠炎和其它胃肠道病症治疗中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012116753A (ja) * 2009-03-26 2012-06-21 Nippon Chemiphar Co Ltd ペルオキシソーム増殖剤活性化受容体の活性化剤
CN105879055A (zh) * 2014-11-11 2016-08-24 董勤 载cxcr4小分子rna聚酰胺树枝状聚合物纳米微粒
JP7088473B2 (ja) * 2015-10-29 2022-06-21 ザ・ジョンズ・ホプキンス・ユニバーシティー ペルオキシソーム障害および白質ジストロフィーの処置のための組成物および方法
US11771702B2 (en) * 2018-11-30 2023-10-03 Amiram Goldblum Agonists of PPAR-δ
AU2020397063A1 (en) * 2019-12-04 2022-07-07 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery
AU2020397064A1 (en) * 2019-12-04 2022-07-07 Ashvattha Therapeutics, Inc. Triantennary N-Acetylgalactosamine modified hydroxyl polyamidoamine dendrimers and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011053618A2 (en) * 2009-10-30 2011-05-05 The Regents Of The University Of Michigan Hydroxyl-terminated dendrimers
CN106573070A (zh) * 2014-08-13 2017-04-19 约翰霍普金斯大学 树枝状聚合物到脑肿瘤的选择性传递
CN108289872A (zh) * 2015-10-29 2018-07-17 约翰霍普金斯大学 树枝状聚合物组合物和其在坏死性小肠结肠炎和其它胃肠道病症治疗中的用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MATSUURA, SATORU等: "L-Serine–modified polyamidoamine dendrimer as a highly potent renal targeting drug carrier", 《 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA》, vol. 115, no. 41, 9 October 2018 (2018-10-09), pages 10511 - 10516 *
SADEKAR, S.等: "Comparative Biodistribution of PAMAM Dendrimers and HPMA Copolymers in Ovarian-Tumor-Bearing Mice", 《BIOMACROMOLECULES》, vol. 12, no. 1, 3 December 2010 (2010-12-03), pages 88 - 96 *
SOIBERMAN, URI等: "Subconjunctival injectable dendrimer-dexamethasone gel for the treatment of corneal inflammation", 《BIOMATERIALS》, vol. 125, 16 February 2017 (2017-02-16), pages 38 - 53 *
YOSSEF ALNASSER等: "Preferential and Increased Uptake of Hydroxyl-Terminated PAMAM Dendrimers by Activated Microglia in Rabbit Brain Mixed Glial Culture", 《MOLECULES》, vol. 23, no. 5, 27 April 2018 (2018-04-27), pages 1 - 14 *

Also Published As

Publication number Publication date
EP4181913A4 (en) 2025-02-19
US20230364244A1 (en) 2023-11-16
CA3189682A1 (en) 2022-01-20
JP2023534812A (ja) 2023-08-14
AU2021310470A1 (en) 2023-03-02
EP4181913A1 (en) 2023-05-24
PH12023550133A1 (en) 2024-06-24
IL299891A (en) 2023-03-01
WO2022016120A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
US20210252153A1 (en) Selective dendrimer delivery to brain tumors
US20230364244A1 (en) Dendrimer compositions and methods for drug delivery to injured kidney
US10172962B2 (en) Macromolecular delivery systems for non-invasive imaging, evaluation and treatment of arthritis and other inflammatory diseases
CN115103690B (zh) 用于将药物递送至眼的树枝状大分子组合物和方法
JP2011500601A (ja) 腫瘍の診断および処置のためのクロロトキシン薬剤の全身性投与
US20160228580A1 (en) Mixed micelles
US20250009894A1 (en) Dendrimer compositions and methods for treatment of severe acute respiratory distress syndrome
ES2925939T3 (es) Polirrotaxanos que contienen especies de ciclodextrinas mixtas y usos de los mismos
HK40093382A (zh) 用於将药物递送至受伤肾脏的树枝状大分子组合物和方法
HK40093332A (zh) 用於治疗重度急性呼吸窘迫综合症的树枝状大分子组合物和方法
US20250352653A1 (en) Neuron targeted 2-deoxyglucose dendrimer for imaging and treatment of neurological diseases
HK40081089A (en) Dendrimer compositions and methods for drug delivery to the eye
CN119454650A (zh) 一种负载槲皮素的级联靶向纳米颗粒及其制备方法和应用
EP4210764A1 (en) Galactosylated dendrimers for targeted intracellular delivery to hepatocytes
WO2022039206A1 (ja) 非アルコール性脂肪肝炎治療用医薬組成物
Qin et al. Precision Medicine for Rheumatoid Arthritis: Chondroitin Sulfate-Based Nanoparticles for Targeted Therapeutics

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40093382

Country of ref document: HK